Cambrex Corporation (NYSE: CBM) is a custom development and manufacturing organization that specializes in products and services that accelerate the development and commercialization of small molecule therapeutics. While the stock has risen some 34% year to date, the company's discounted valuation and upcoming catalysts could suggest greater upside ahead. In this article, we will take a look at both of these drivers in greater detail.
A Brief Primer
Cambrex generates the majority of its revenues from custom development and manufacturing (45%), with generics (36%), control substances (14%) and drug delivery (5%) rounding out its business. With R&D and cGMP manufacturing facilities in the U.S., Europe and India, the company provides APIs, advanced intermediates, drug delivery products and custom development...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|